A5049062198- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Multiple and Secondary Primary Cancers
- Neuroendocrine Tumor Research Advances
- Cancer Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Cancer Treatment and Pharmacology
- Glioma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- COVID-19 Clinical Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- Brain Metastases and Treatment
- SARS-CoV-2 and COVID-19 Research
- Myasthenia Gravis and Thymoma
- Peptidase Inhibition and Analysis
- Breast Implant and Reconstruction
- Cancer survivorship and care
Complexo Hospitalario Universitario A Coruña
2015-2024
Universidade da Coruña
2016-2024
Servicio Gallego de Salud
2016-2024
Instituto de Investigación Biomédica de A Coruña
2021-2024
Hospital Central de las Fuerzas Armadas
2024
RedCLARA
2024
Clínica CES
2024
Universidad del Rosario
2024
Institut Català d'Oncologia
2014-2023
Hospital Universitario Puerta de Hierro Majadahonda
2023
Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis stage III disease. There is no current consensus regarding the most appropriate treatment for these patients.In this open-label, phase 2 trial, we randomly assigned resectable IIIA or IIIB NSCLC to neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) alone (control group), followed by surgery. Patients in experimental group who had R0 resections received adjuvant 6 months. The...
The Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients advanced non-small-cell lung cancer (NSCLC) untreated brain metastases, a population traditionally excluded from trials.This single-arm phase II clinical trial enrolled nonsquamous NSCLC metastases without neurologic symptoms or asymptomatic medical treatment. Dexamethasone was allowed up to 4 mg once daily. Atezolizumab plus carboplatin and pemetrexed given for four six cycles followed by until progression...
8501 Background: Non-small cell lung cancer (NSCLC) is incurable in most patients with locally advanced stage IIIA disease. Previous results indicate that the use of neoadjuvant chemoimmunotherapy could increase percentage cured being a promising therapeutic option has to be tested randomized clinical trials. Methods: NADIM II (NCT03838159) an open-label, randomized, two-arm, phase II, multi-center trial. Patients resectable (per AJCC 7 th ed) NSCLC, ECOG PS 0-1, and no known EGFR/ALK...
Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data real life is lacking. This an observational study that represents world experience with nivolumab pretreated NSCLC.Eligibility criteria included, histologically confirmed NSCLC, stage IIIB and IV, evaluable disease at least one prior therapy. Patients received until progressive (PD) or unacceptable toxicity. The main aim was to report efficacy safety profile...
Background: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to worsen it. We evaluated outcomes NSCLC treated agents relation presence irAEs and reasons for using corticosteroids: whether palliative cancer-related or management irAEs. Methods: Clinical were calculated regard corticosteroids. A landmark analysis was...
Patients with cancer may be at increased risk of more severe COVID-19 disease; however, prognostic factors are not yet clearly identified. The GRAVID study aimed to describe clinical characteristics, outcomes, and predictors poor outcome in patients lung COVID-19.Prospective observational that included medical records PCR-confirmed diagnosis across 65 Spanish hospitals. primary endpoint was all-cause mortality; secondary endpoints were hospitalization admission intensive care units (ICU).A...
Lorlatinib, a third-generation tyrosine kinase inhibitor (TKI), targets both ALK and ROS1 rearrangements in non-small cell lung cancer (NSCLC). It is approved for ALK-positive patients after progression on prior TKIs but lacks FDA or EMA approval ROS1-positive NSCLC. This study evaluates lorlatinib's efficacy safety ALK- through compassionate use program Spain. We analyzed treated from November 2016 to February 2019 March 2021. Eligible had Stage IV NSCLC with confirmed TKI therapy. For...
Abstract Background The aim, of the study was to estimate accuracy magnetic resonance imaging (MRI) in assessing residual disease breast cancer patients receiving neoadjuvant chemotherapy (NAC) and identify clinico-pathological factors that affect diagnostic MRI determine tumour size following NAC. Patients methods 91 undergoing NAC (92 lesions) were included study. Breast performed at baseline after completion Treatment response evaluated by histopathological examination investigate ability...
The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell cancer (NSCLC) patients for anti-programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate the first time best of our knowledge and predictive utility LIPI in multicenter nivolumab monotherapy-based cohort. We retrospectively analyzed influence baseline on overall survival (OS), progression-free (PFS), disease...
The National Comprehensive Cancer Network guidelines recommend re-challenge with the first-line treatment for relapsed small cell lung cancer (SCLC) chemotherapy-free interval (CTFI)≥180 days. A phase II study (NCT02454972) showed remarkable antitumor activity in SCLC patients treated lurbinectedin 3.2 mg/m2 1 -h intravenous infusion every 3 weeks as second-line therapy. We report results pre-planned subset of CTFI ≥ 180 days.Twenty aged ≥18 years pathologically proven diagnosis, pretreated...
Breast cancer is the most diagnosed worldwide and represents fifth cause of mortality globally. It a highly heterogeneous disease, that comprises various molecular subtypes, often by immunohistochemistry. This technique widely employed in basic, translational pathological anatomy research, where it can support oncological diagnosis, therapeutic decisions biomarker discovery. Nevertheless, its evaluation qualitative, raising need for accurate quantitation methodologies. We present software...
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are overexpressed in the majority of renal cell carcinomas. This characteristic has supported rationale targeting VEGF-driven tumour vascularization, especially clear RCC. VEGF-inhibiting strategies include use tyrosine kinase inhibitors (sunitinib, axitinib, pazopanib, sorafenib) neutralizing antibodies such as bevacizumab. Hypertension (HTN) is one most common adverse effects angiogenesis inhibitors. HTN observed clinical...
Lung cancer causes approximately 25% of all deaths. Despite its relevance, few studies have analyzed differences by sex at the time diagnosis in terms symptoms, stage, age or smoking status. We aim to assess if there are between men and women on these characteristics diagnosis.We Thoracic Tumour Registry (TTR), sponsored Spanish Cancer Group using a case-series design. This is nationwide registry lung cases which started recruitment 2016. For each case included, clinicians fulfilled an...
Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but information on the efficacy anti-SARS-CoV-2 vaccine in these patients is scarce. We aimed evaluating safety immunogenicity COVID-19 vaccines this population.The prospective, nationwide SOLID substudy, enrolled adults who were fully vaccinated against COVID-19. Serum IgG antibody levels quantitatively assessed two weeks six months after receipt last dose using a chemiluminescent...